

中文題目：南部地區客製化幽門螺旋桿菌根除法療效之分析

英文題目：The Efficacy of Rescue *Helicobacter pylori* Eradication Rate by Tailored Made Therapies in Southern Taiwan

作者：許文鴻^{1,2} 胡晃鳴^{1,2} 李易謙¹ 吳政毅^{1,3} 許秉毅⁴ 郭昭宏^{1,2*}

服務單位：高雄醫學大學附設中和紀念醫院 胃腸內科 1

高雄醫學大學 醫學系²

高雄市立小港醫院 內科³

高雄榮民總醫院 胃腸科⁴

Background: The resistance of *Helicobacter pylori* (*H. pylori*) to antibiotics is increasing in Southern Taiwan, affecting the efficacy in current eradication therapies. The prospective study was designed to survey the efficacies between tailored-made and conventional therapies after failure of second- or third -line therapies in Southern Taiwan.

Patients and methods: From September 2012 and October 2015, 81 patients with failure of eradicating *H. pylori* by second or third-line therapies were enrolled in our study. 53 patients with culture-positive result were assigned to receive tailored-made therapies (T-group). 28 patients with culture-negative results were assigned to receive conventional second-line therapies (C-group). C-group principally received quadruple therapies. Follow-up endoscopy or C¹³-urea breath test (UBT) was done 16 weeks later to assess the treatment response. Patients' responses and CYP2C19 genotypes were also examined.

Results: Intention-to-treat analysis (N=81) revealed that two groups showed significantly different eradication rates (T-group: 84.9 %; 95%CI: 80.1 %-89.3% and C-group: 53.6 %; 95% CI: 49.5%-60.9%) (p value= 0.002). Per-protocol analysis (N=77) results showed that two groups showed significantly different eradication rates (T-group: 86.5%; 95%CI: 80.7%-91.3% and C-group: 60.0%; 95% CI: 55.5%-64.9%) (p-value= 0.086). We did not find significant different compliance and adverse events between two groups. Logistic regression analysis showed that only compliance was important predictor for eradication failure. *CYP2C19* polymorphism did not influence the eradicating effect.

Conclusion: We found that tailored-made therapies were more suitable than conventional therapies for rescue therapies of *H. pylori*. So it is reliable that tailored-made quadruple therapies should be the better choice for patients receiving rescue therapy of *H. pylori* in high resistant area.